-
货号
KDC82402
-
描述
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human MAPT has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Tilavonemab in the sample competitively binds to the pre-coated protein with biotin-labeled Tilavonemab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Tilavonemab bound in the initial step. The color development is stopped and the intensity of the color is measured.
-
应用
Used for the quantitative determination of Tilavonemab concentration in serum and plasma. -
检测方法
Colorimetric -
样本类型
Plasma, Serum -
实验类型
Quantitative -
检测范围
234.38 - 15,000 ng/mL -
灵敏度
408.16 ng/mL -
精准度
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
Intra-Assay Precision
Inter-Assay Precision
Sample
1
2
3
1
2
3
n
16
16
16
24
24
24
Mean (ng/mL)
7674.19
1588.31
511.30
7516.36
1691.74
493.15
Standard deviation
1064.41
116.69
57.53
415.73
149.84
98.89
CV (%)
13.87
7.35
11.25
5.53
8.86
20.05
-
回收率
80-120% -
运输
2-8 ℃ -
稳定性和存储
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. -
别名
ABBV-8E12, C2N-8E12, CAS: 2096513-89-0
-
背景
Tilavonemab (ABBV-8E12) is an antibody recognizing the aggregated, extracellular form of pathological tau and binding to the N-terminus of tau. This drug was developed by C2N Diagnostics and AbbVie and has been validated for its safety in a phase I trial. However, the phase II trial, evaluating the efficacy and safety of tilavonemab in 453 patients with early AD, did not obtain expected results and now tilavonemab is discontinued in AD treatment. In addition, a phase II trial purposed to assess the long-term safety and tolerability of tilavonemab in 364 participants with early AD was finished in September 30, 2021, but its final reports are not available.
